Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide does a lot of the heavy lifting on its own, but the decisions you make around it — what you eat, how you move, how consistently you use it — genuinely shape how much weight you lose. Most people starting Mounjaro want to know whether there are things they can do to make it work harder. There are. And they are more straightforward than you might expect. These are prescription-only medicines that must be assessed and supervised by a qualified prescriber before and during use, so the specifics of your dose and titration always sit with your clinical team, but the supporting habits described here are evidence-informed and widely recommended alongside treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is the most common misunderstanding, and it's worth addressing plainly. Tirzepatide works by activating the GIP and GLP-1 receptors that regulate appetite and blood-sugar response, slowing gastric emptying and reducing how much food you feel you need. That is a powerful mechanism. In the SURMOUNT-1 trial, participants using the highest doses lost around 20–21% of their body weight over 72 weeks, figures published in the New England Journal of Medicine and reviewed as part of NICE's appraisal of tirzepatide (TA1026).
Those numbers came from trials where participants also followed a reduced-calorie diet and increased their physical activity. That is not a footnote, it is part of the licensed indication. The medicine's UK licence covers weight management alongside both of those lifestyle elements. People who treat tirzepatide as a substitute for behaviour change rather than a support for it tend to see slower results and find the plateau arrives earlier. The medicine reduces hunger; it does not change what you choose to eat when hunger does return, or how sedentary a day is.
If you have been a few weeks in and the scale has barely moved, the honest question is not whether the medicine is working, it is whether the conditions around it are giving it the best chance. That is a much more useful question to sit with, and most of the answers are in the sections below. You can also read more about how effective Mounjaro tends to be in practice, and what shapes those outcomes, on this site.
One of the more counterintuitive aspects of GLP-1 and GIP treatment is that appetite suppression can work against you nutritionally. When you are eating significantly less, hitting adequate protein becomes harder, and protein is the macronutrient that preserves lean muscle during weight loss and keeps you feeling full between doses. A useful working target for most adults is around 1.2–1.6g of protein per kilogram of body weight per day, though your prescriber or a dietitian can give you a figure tailored to your situation.
Meal structure also matters. Many people on tirzepatide find that front-loading protein and vegetables into the first part of a meal, before starchy foods, sits more comfortably and supports steadier blood-sugar levels. Smaller, more frequent meals tend to cause fewer GI symptoms than large ones, particularly in the first weeks of treatment or after a dose increase. The NHS patient information for tirzepatide recommends eating smaller portions and avoiding high-fat foods to reduce nausea, which aligns with this approach.
Ultra-processed foods deserve a specific mention. They are engineered to override satiety signals, precisely the signals tirzepatide is trying to amplify. A meal of highly processed food can blunt the feeling of fullness the medicine creates in a way that whole foods do not. That is not a moral judgement about food; it is a practical observation about how these foods interact with the medicine's mechanism.
Aerobic exercise burns calories; resistance exercise does something additional, it signals to the body that lean muscle is worth keeping. During significant calorie restriction, the body will draw on muscle as well as fat for energy unless that muscle is being actively used. A 2024 meta-analysis suggested that adding resistance training to GLP-1 treatment meaningfully reduced the proportion of weight lost from lean tissue compared to no exercise. Walking, cycling or swimming three to five times a week alongside two resistance sessions is a reasonable starting point, though intensity and duration should fit your current fitness level rather than an ideal on paper.
Some people starting Mounjaro find exercise harder in the first few weeks because energy dips while the body adjusts to lower calorie intake. That usually settles. Starting with shorter sessions and building gradually is more sustainable than an ambitious week-one plan that gets abandoned. Strength training does not need a gym, bodyweight exercises at home count. The point is consistency over months, not heroism in week one. If you want a broader picture of how tirzepatide fits into a weight-loss plan, the tirzepatide overview on this site covers the mechanism and licensed use in more detail.
Subcutaneous absorption of tirzepatide is influenced by where and how you inject. Rotating sites between the abdomen, thigh and upper arm matters, injecting repeatedly into the same spot can cause localised tissue changes that affect absorption. Injecting into an area with active scar tissue or a recent bruise has a similar effect. The injection should go into fatty tissue just beneath the skin, not into muscle. The Patient Information Leaflet included with your pens covers the correct technique; reading it properly on first use rather than skipping to the injection diagram is worthwhile.
Consistency of dosing day matters too. Taking each weekly dose within a narrow window of the same day each week keeps plasma levels steadier. Dose timing questions (including what to do if you miss a dose) go to your prescriber and the Patient Information Leaflet rather than online estimates.
Alcohol is worth a frank mention. Beyond its own calorie contribution, alcohol lowers inhibitions around food choices, disrupts sleep (which affects ghrelin and hunger hormones), and can worsen GI side effects in people on tirzepatide. It does not need to be eliminated, but reducing it is one of the more effective supporting changes people can make, particularly early in treatment. Questions about how treatment works at different stages of the titration schedule are worth raising at your next clinical review, or, if you are considering starting, a free consultation with our prescribers is the right place to start. You can also look at our overview of when Mounjaro tends to be most effective across the treatment course, and if cost is part of your thinking, the Mounjaro cost guide explains what a transparent private price should include. If you are also weighing up whether an oral form of tirzepatide would be as effective as the injectable version, we cover that question separately. Once you are ready, starting your free consultation is the next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.